Bristol Myers Squibb and Nvidia said they will expand pharma’s AI compute footprint, targeting “the most powerful AI factory in life sciences.” BMS plans to build new infrastructure around an NVIDIA DGX SuperPOD system enabled with AIDGX Vera Rubin NVL72 systems, with BMS positioning it as an energy-efficient, single-owned Nvidia setup. The expansion follows a three-year Nvidia collaboration that initially deployed DGX SuperPOD for BMS R&D. BMS said the upgraded platform is intended to support a “hybrid intelligence” workflow—pairing AI co-scientists with human researchers to increase the likelihood programs advance on the right hypotheses. The announcement places BMS among multiple major pharma companies investing heavily in Nvidia partnerships and data-center scale computing as they pursue more automated discovery and operational efficiencies. BMS also cited other AI initiatives, including collaborations tied to Anthropic and Microsoft deployments in clinical-adjacent workflows.